Literature DB >> 17597096

A stop codon mutation in SCN9A causes lack of pain sensation.

Sultan Ahmad1, Leif Dahllund, Anders B Eriksson, Dennis Hellgren, Urban Karlsson, Per-Eric Lund, Inge A Meijer, Luc Meury, Tracy Mills, Adrian Moody, Anne Morinville, John Morten, Dajan O'donnell, Carina Raynoschek, Hugh Salter, Guy A Rouleau, Johannes J Krupp.   

Abstract

The general lack of pain experience is a rare occurrence in humans, and the molecular causes for this phenotype are not well understood. Here we have studied a Canadian family from Newfoundland with members who exhibit a congenital inability to experience pain. We have mapped the locus to a 13.7 Mb region on chromosome 2q (2q24.3-2q31.1). Screening of candidate genes in this region identified a protein-truncating mutation in SCN9A, which encodes for the voltage-gated sodium channel Na(v)1.7. The mutation is a C-A transversion at nucleotide 984 transforming the codon for tyrosine 328 to a stop codon. The predicted product lacks all pore-forming regions of Na(v)1.7. Indeed, expression of this altered gene in a cell line did not produce functional responses, nor did it cause compensatory effects on endogenous voltage-gated sodium currents when expressed in ND7/23 cells. Because a homozygous knockout of Na(v)1.7 in mice has been shown to be lethal, we explored why a deficiency of Na(v)1.7 is non-lethal in humans. Expression studies in monkey, human, mouse and rat tissue indicated species-differences in the Na(v)1.7 expression profile. Whereas in rodents the channel was strongly expressed in hypothalamic nuclei, only weak mRNA levels were detected in this area in primates. Furthermore, primate pituitary and adrenal glands were devoid of signal, whereas these two glands were mRNA-positive in rodents. This species difference may explain the non-lethality of the observed mutation in humans. Our data further establish Na(v)1.7 as a critical element of peripheral nociception in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597096     DOI: 10.1093/hmg/ddm160

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  Extending the clinical spectrum of pain channelopathies.

Authors:  Henry Houlden
Journal:  Brain       Date:  2012-02       Impact factor: 13.501

Review 2.  Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations.

Authors:  Ron Dabby
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

3.  A nonsense mutation in the SCN9A gene in congenital insensitivity to pain.

Authors:  Mazen Kurban; Muhammad Wajid; Yutaka Shimomura; Angela M Christiano
Journal:  Dermatology       Date:  2010-07-13       Impact factor: 5.366

4.  Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (μ-TRTX-Hh2a).

Authors:  Natali A Minassian; Alan Gibbs; Amy Y Shih; Yi Liu; Robert A Neff; Steven W Sutton; Tara Mirzadegan; Judith Connor; Ross Fellows; Matthew Husovsky; Serena Nelson; Michael J Hunter; Mack Flinspach; Alan D Wickenden
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

Review 5.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

6.  Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents.

Authors:  John Gilchrist; Stacey Dutton; Marcelo Diaz-Bustamante; Annie McPherson; Nicolas Olivares; Jeet Kalia; Andrew Escayg; Frank Bosmans
Journal:  ACS Chem Biol       Date:  2014-03-31       Impact factor: 5.100

Review 7.  Distribution and function of voltage-gated sodium channels in the nervous system.

Authors:  Jun Wang; Shao-Wu Ou; Yun-Jie Wang
Journal:  Channels (Austin)       Date:  2017-11-08       Impact factor: 2.581

8.  Co-expression of β Subunits with the Voltage-Gated Sodium Channel NaV1.7: the Importance of Subunit Association and Phosphorylation and Their Effects on Channel Pharmacology and Biophysics.

Authors:  Maxim V Sokolov; Petra Henrich-Noack; Carina Raynoschek; Bo Franzén; Olof Larsson; Martin Main; Michael Dabrowski
Journal:  J Mol Neurosci       Date:  2018-05-10       Impact factor: 3.444

9.  Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations.

Authors:  James J Cox; Jony Sheynin; Zamir Shorer; Frank Reimann; Adeline K Nicholas; Lorena Zubovic; Marco Baralle; Elizabeth Wraige; Esther Manor; Jacov Levy; C Geoffery Woods; Ruti Parvari
Journal:  Hum Mutat       Date:  2010-09       Impact factor: 4.878

10.  In vivo and ex vivo inhibition of spinal nerve ligation-induced ectopic activity by sodium channel blockers correlate to in vitro inhibition of NaV1.7 and clinical efficacy: a pharmacokinetic-pharmacodynamic translational approach.

Authors:  Ivana Kalezic; Lei Luo; Per-Eric Lund; Anders B Eriksson; Tjerk Bueters; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-02-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.